Table 3.
Demographics and clinical characteristics at study baseline by assigned treatment and ADRB1-rs1801253 genotype
| CG or GG Genotype (n=52) | CC Genotype (n=70) | CG or GG Genotype (n=50) | CC Genotype (n=71) | |
|---|---|---|---|---|
| Age at randomization, years | ||||
| Mean ± SD | 13.2 ± 6.4 | 11.3 ± 6.6 | 11.1 ± 6.3 | 11.8 ± 6.2 |
| Median (IQR) | 11.9 (8.1, 18.7) | 11.0 (5.3, 14.9) | 9.5 (5.9, 16.1) | 12.1 (6.9, 15.4) |
| Male | 28 (53.8%) | 41 (58.6%) | 33 (66.0%) | 48 (67.6%) |
| Presence of causal FBN1 variant‡ | 14 (26.9%) | 25 (35.7%) | 10 (20.0%) | 25 (35.2%) |
| Family history of Marfan syndrome | 28 (53.8%) | 42 (60.0%) | 29 (58.0%) | 44 (62.0%) |
| Maximum aortic-root diameter | ||||
| Mean ± SD | 3.5 ± 0.7 | 3.3 ± 0.7 | 3.4 ± 0.7 | 3.4 ± 0.7 |
| Median (IQR) | 3.6 (3.0, 4.0) | 3.3 (2.8, 3.9) | 3.5 (2.8, 3.9) | 3.3 (2.9, 4.0) |
| Maximum aortic-root diameter z-score | ||||
| Mean ± SD | 4.3 ± 1.1 | 4.1 ± 1.0 | 4.5 ± 1.2 | 4.1 ± 1.1 |
| Median (IQR) | 4.1 (3.6, 4.7) | 4.0 (3.5, 4.7) | 4.0 (3.5, 5.4) | 3.9 (3.3, 4.8) |
| Max aortic-root diameter z-score ≥ 4.5 | 18 (34.6%) | 19 (27.1%) | 21 (42.0%) | 20 (28.2%) |
SD – Standard Deviation; IQR – Interquartile Range.
*
4 / 126 individuals in the atenolol treatment group failed genotyping for rs1801253.
†
3/124 individuals in the losartan treatment group failed genotyping for rs1801253.
‡
no presence of causal FBN1 variant includes absent and unknown status.